Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Artificial Intelligence Applied to clinical trials: opportunities and challenges
by
Calado, Gilda
, Askin, Scott
, El Dakrouni, Samar
, Burkhalter, Denis
in
Artificial intelligence
/ Biological and Medical Physics
/ Biomedical Engineering and Bioengineering
/ Biomedicine
/ Biophysics
/ Clinical trials
/ Collaboration
/ Computational Biology/Bioinformatics
/ Documents
/ Drug development
/ Engineering
/ Ethical standards
/ Evolution
/ Machine learning
/ Medicine/Public Health
/ Oncology
/ Pharmaceutical industry
/ R & D/Technology Policy
/ Regulatory agencies
/ Regulatory approval
/ Review Paper
/ Statistical analysis
2023
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Artificial Intelligence Applied to clinical trials: opportunities and challenges
by
Calado, Gilda
, Askin, Scott
, El Dakrouni, Samar
, Burkhalter, Denis
in
Artificial intelligence
/ Biological and Medical Physics
/ Biomedical Engineering and Bioengineering
/ Biomedicine
/ Biophysics
/ Clinical trials
/ Collaboration
/ Computational Biology/Bioinformatics
/ Documents
/ Drug development
/ Engineering
/ Ethical standards
/ Evolution
/ Machine learning
/ Medicine/Public Health
/ Oncology
/ Pharmaceutical industry
/ R & D/Technology Policy
/ Regulatory agencies
/ Regulatory approval
/ Review Paper
/ Statistical analysis
2023
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Artificial Intelligence Applied to clinical trials: opportunities and challenges
by
Calado, Gilda
, Askin, Scott
, El Dakrouni, Samar
, Burkhalter, Denis
in
Artificial intelligence
/ Biological and Medical Physics
/ Biomedical Engineering and Bioengineering
/ Biomedicine
/ Biophysics
/ Clinical trials
/ Collaboration
/ Computational Biology/Bioinformatics
/ Documents
/ Drug development
/ Engineering
/ Ethical standards
/ Evolution
/ Machine learning
/ Medicine/Public Health
/ Oncology
/ Pharmaceutical industry
/ R & D/Technology Policy
/ Regulatory agencies
/ Regulatory approval
/ Review Paper
/ Statistical analysis
2023
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Artificial Intelligence Applied to clinical trials: opportunities and challenges
Journal Article
Artificial Intelligence Applied to clinical trials: opportunities and challenges
2023
Request Book From Autostore
and Choose the Collection Method
Overview
Background
Clinical Trials (CTs) remain the foundation of safe and effective drug development. Given the evolving data-driven and personalized medicine approach in healthcare, it is imperative for companies and regulators to utilize tailored Artificial Intelligence (AI) solutions that enable expeditious and streamlined clinical research. In this paper, we identified opportunities, challenges, and potential implications of AI in CTs.
Methods
Following an extensive search in relevant databases and websites, we gathered publications tackling the use of AI and Machine Learning (ML) in CTs from the past 5 years in the US and Europe, including Regulatory Authorities’ documents.
Results
Documented applications of AI commonly concern the oncology field and are mostly being applied in the area of recruitment. Main opportunities discussed aim to create efficiencies across CT activities, including the ability to reduce sample sizes, improve enrollment and conduct faster, more optimized adaptive CTs. While AI is an area of enthusiastic development, the identified challenges are ethical in nature and relate to data availability, standards, and most importantly, lack of regulatory guidance hindering the acceptance of AI tools in drug development. However, future implications are significant and are anticipated to improve the probability of success, reduce trial burden and overall, speed up research and regulatory approval.
Conclusion
The use of AI in CTs is in its relative infancy; however, it is a fast-evolving field. As regulators provide more guidance on the acceptability of AI in specific areas, we anticipate the scope of use to broaden and the volume of implementation to increase rapidly.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
This website uses cookies to ensure you get the best experience on our website.